2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Longitude Prime Fund II | August 2022 | $200M | $50M | 10 |
| Longitude Prime FundFiled to raise in 2021, with no closing reported yet. | 2021 | $130M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Patrick Enright | Selective | Biotech & pharma, Logistics & supply chain, Real estate & proptech | 18 |
Classified sectors of Longitude Prime’s own portfolio companies, based on 19 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Longitude Prime’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Longitude 103.8 East | 20 | Aimmune Therapeutics, Aptinyx, BioAge Labs, CARDIODX, Ceribell, CuraSen Therapeutics, Endeavor Biomedicines, Esperion Therapeutics, INFACARE PHARMACEUTICAL, Infinant Health, Orbus Therapeutics, Rivus Pharmaceuticals, Rock Starr, Rockpoint, Stichting Administratiekantoor syncreon, SutroVax, Venus Concept, Vera Therapeutics, Veradermics, Zenas BioPharma (Cayman) |
| Longitude Capital | 20 | Aimmune Therapeutics, Aptinyx, BioAge Labs, CARDIODX, Ceribell, CuraSen Therapeutics, Endeavor Biomedicines, Esperion Therapeutics, INFACARE PHARMACEUTICAL, Infinant Health, Orbus Therapeutics, Rivus Pharmaceuticals, Rock Starr, Rockpoint, Stichting Administratiekantoor syncreon, SutroVax, Venus Concept, Vera Therapeutics, Veradermics, Zenas BioPharma (Cayman) |
| 2 |
| Juliet Tammenoms Bakker | Quiet | Medical devices | 2 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 3 |
| BioAge Labs, Venus Concept, Vera Therapeutics |
| Venbio Select | 3 | Orbus Therapeutics, SutroVax, Vera Therapeutics |
| New Leaf | 2 | Aptinyx, CuraSen Therapeutics |
| Aperture | 1 | Venus Concept |
| Bain Capital Life Sciences | 1 | Aptinyx |
| Capra CLO Founders | 1 | BioAge Labs |
| Domain Partners | 1 | Esperion Therapeutics |
| Healthquest Partners | 1 | Venus Concept |
| Versant Affiliates | 1 | Ceribell |
| Versant Venture Capital | 1 | Ceribell |
| Vivo Innovation | 1 | Zenas BioPharma (Cayman) |
| Westlake Biopartners | 1 | Vera Therapeutics |
A shared board seat: a company where filings name a Longitude Prime partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
